Pharmacy worker who stole weight loss drug Ozempic and sold it on black market is spared jail
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
21 minutes ago
- Telegraph
Third of young people want fat jabs as demand spirals
A third of young adults want to take fat jabs amid a surge in demand for the drugs, pharmacists have said. One in five people say they have tried to access a pharmacy weight-loss treatment in the past year but this figure is 35 per cent for those aged between 16 and 34. Pharmacists have raised the alarm that demand has far exceeded what can be clinically delivered. Concerns have also been raised that people could resort to looking for drugs such as Wegovy and Mounjaro from online sellers. Current guidelines state that patients being prescribed Mounjaro and Wegovy through pharmacies need a BMI of at least 35 and at least one weight-related comorbidity, such as diabetes, to be eligible. Wegovy can also be prescribed to patients with a BMI of 30–34 who meet the criteria for referral to specialist overweight and obesity management services. However, the NHS is only rolling out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities. It spent £269million on fat jabs in 2024-2025 and prescriptions doubled to almost three million a year. Mounjaro, regarded as the strongest jab and known as King Kong, has driven the spike in prescriptions with 1.1million given out in a year compared with 3,300 in the previous 12 months. The National Pharmacy Association (NPA), which represents about 6,000 pharmacies, surveyed 2,000 Britons and found evidence of demand beyond what the NHS can offer. It is now seeking greater clarity on how pharmacies will be further involved in the distribution of weight-loss medication, something laid out in the Government's recent 10 Year Health Plan. Olivier Picard, chairman of the NPA, said: 'Weight-loss jabs are one of the biggest drug innovations this century but growing demand highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight-loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from medication. 'We're also urging the Government to bring forward plans to include pharmacies in the rollout of their NHS weight-management programme. 'Pharmacists are experts in medication and many have extensive experience delivering weight-loss injections as part of a package of care including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS and help people make the best use of these powerful medicines,' he added
Telegraph
an hour ago
- Telegraph
Prostate cancer checks soar after Sir Chris Hoy reveals diagnosis
Thousands more men are having checks for prostate cancer since Sir Chris Hoy revealed he had been diagnosed with the disease and was terminally ill. The six-time Olympic cycling gold medallist was told in 2023 that he was terminally ill with cancer that originated in his prostate, and shared his diagnosis publicly last year. Despite a family history of prostate cancer – which also affected his father and grandfather – Sir Chris was never offered the PSA test that could have detected it. New NHS data show almost 5,000 extra men have been referred for urological cancer in the six months after Sir Chris, 49, spoke out, a trend described by experts as 'staggering'. The figures, from October 2024 to March 2025, show 138,734 men were given an urgent referral for urological cancers, with prostate cancer the main form of disease. This amounts to an extra 4,962 cases compared with the same six-month period in 2023-24. Separate data show a huge increase in the number of men with a family history of prostate cancer who have assessed their own risk. The number of men with such a history who have used an online risk checker to assess their chances of the disease rose by 77 per cent over the period. Telegraph launches screening campaign The findings have been released as The Telegraph launches a campaign calling for the introduction of targeted screening for prostate cancer. Men are not offered tests currently, even if they have a family history of the disease. Experts believe there is a growing case for targeted screening, meaning that PSA blood tests would be offered to those at heightened risk of the disease. Peter Kyle, the Science Secretary, hopes to harness AI and data to improve prostate cancer screening for high-risk men which factors in family history, genetics, demographics and other factors. Mr Kyle, writing in The Telegraph, said he hopes researchers can harness the vast amount of health data available to 'develop AI-powered tools that can predict cancer risk' to save thousands of lives a year. The UK National Screening Committee is currently considering whether to recommend the introduction of mass testing. 'I told my story to raise awareness' Sir Chris said: 'I was diagnosed with stage four prostate cancer at 47. By this age, my prostate cancer was advanced and could have been progressing from when I was 45 or even younger. With prostate cancer, the earlier you find it, the easier it is to treat. We need the system to change to enable more men to get diagnosed earlier, and stop them getting the news I got. 'That's why I believe men at highest risk, for example men with a family history like me, or black men, should be contacted by their GP earlier on to discuss a simple PSA blood test that can check for signs of prostate cancer. 'Then if there are any issues, they can get it treated it at an earlier stage. 'I've told my story to help raise awareness about the most common cancer in men and get more thinking about their risk and what they can do, but it shouldn't all be men's responsibility.' The online risk checking tool, published by Prostate Cancer Research UK, asks men simple questions about their family history and ethnicity to determine risk levels, and gives advice about what help to seek. The charity found that the number of men undergoing the check rose by 45 per cent overall, when data from October 2024 to February 2025 was compared with the same period the year before. The sharpest increase by far came from men aged between 45 and 49, with a family history of the disease. In total 10,427 such men checked their risk, compared with 5,891 in the same period the previous years. In total there were 688,796 checks during the period, up from 473, 843 the year before.
Metro
an hour ago
- Metro
GP reveals 5 common mistakes people make when stopping weight loss jabs
While treatments like Ozempic, Mounjaro and Wegovy can provide a helping hand, there's no magic bullet when it comes to losing weight. Given GLP-1 agonist medications have been shown to help people lose up to four times more than going it alone, it's no wonder they're popular. However, a proportion of the estimated 1.5 million people in the UK who are now on these jabs will struggle to keep the pounds off long-term — and some may even end up heavier than when they started. 'While it can differ depending on the individual, it's quite common for people to regain some of the weight lost once they stop taking the medication,' Dr Donald Grant, GP and senior clinical advisor at The Independent Pharmacy, tells Metro. There are a few factors behind this, from metabolism to appetite. But going back on your progress isn't inevitable, as long as you're careful to avoid these five common pitfalls. As these treatments work by suppressing appetite, Dr Grant warns that going cold turkey 'could increase it, leading to poor eating habits and potential weight gain.' If you're considering coming off your medication, he recommends speaking to your GP about doing so slowly and safely. 'A medical professional can advise further on a potential tapering plan, while also providing dietary advice and lifestyle habits that can help reduce weight gain,' he adds. According to a recent study of over 6,000 people by scientists at Oxford University, those who use GLP-1 drugs will put their weight back on within 10 months of stopping if they don't continue to maintain a healthy lifestyle. Dr Grant explains: 'When stopping weight loss injections, it's crucially important that individuals replace the treatment with another way to keep weight off.' Even 30 minutes of daily exercise can make all the difference, burning off some of those extra calories you're consuming and stopping you falling into a sedentary routine. Quick fixes and 'crash diets' rarely result in any lasting improvements — and the same is true for GLP-1 medications. 'Choosing to stop weight loss treatment too early is by far one of the most common errors people make,' says Dr Grant. 'These drugs are designed to be used long-term, but not doing so gives the body little time to adapt to the treatment.' It's a marathon, not a sprint, with many providers recommending a course of between 12 and 24 months. Unless you're prepared to make that commitment, you may not reap the full benefits of treatment. Making changes to your diet while taking Ozempic, Mounjaro or Wegovy is a vital step to maintaining your progress forward. In fact, Dr Grant claims failure to do so is a 'sure-fire way to regain weight lost'. 'It's important for people to draw up a dietary plan, including structured meal times to avoid overeating,' he explains. More Trending 'I also recommend a well-balanced diet including a variety of high-protein, fibre-rich and healthy fat foods.' 'While it's important not to create an unhealthy relationship with weight management, tracking weight closely once ending any treatments can help people adjust their routine to avoid losing progress,' says Dr Grant. It's easy to revert to old habits once you end a course of medication, but regular monitoring ensures you can get back on track before you lose too much progress. View More » Since you've put so much time, energy and potentially money into the progress you've made so far, just think of this as protecting your investment. Do you have a story to share? Get in touch by emailing MetroLifestyleTeam@ MORE: 'I've tried jabs and pills to lose weight – but my latest attempt is the most extreme' MORE: Lives at risk because we've already forgotten a basic mantra MORE: The golden rule for how long it should take you to pee Your free newsletter guide to the best London has on offer, from drinks deals to restaurant reviews.
